Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
about
HUS and atypical HUS.Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection.Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case ReportRoutine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies.Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?Differential diagnosis of thrombotic microangiopathy in nephrology.Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.Diseases of complement dysregulation-an overview.Thrombotic Microangiopathy and the Kidney.Atypical hemolytic uremic syndrome and eculizumab therapy in children.
P2860
Q33441069-4AF00961-9472-47BB-B0A6-72B682D672CAQ33441408-7A1D6643-15B3-44A5-B945-7441E600E6F9Q33442695-865C1FD9-6709-4F8E-A73E-9531116F1843Q38655720-DFB943E0-1233-4730-9970-984BBB5D8867Q38907049-61D23D02-E621-4C16-8961-907AA607F9B9Q40324683-42999207-E85D-456B-A179-FC468721C0F6Q42000134-0CE2B25E-10AA-48A0-A05A-6E43361E5FB7Q42610013-6DBEA3EC-4A88-4379-90B3-590CA8AA1BFEQ47225732-5FC64997-2C33-425E-A2F4-43550B7C7F1BQ48256943-4BA86E14-9482-4865-9D9D-CFDF90C8696CQ50085453-1F344EB7-79CB-41CD-847B-6183D9A90EC8Q54207419-92A2151E-BC96-4FD3-94E8-C9DA1C84926D
P2860
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@en
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@nl
type
label
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@en
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@nl
prefLabel
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@en
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@nl
P2093
P2860
P356
P1476
Pathogenic Variants in Complem ...... er Eculizumab Discontinuation.
@en
P2093
Alexandre Karras
Aude Servais
Chantal Loirat
Christelle Barbet
Cédric Rafat
Eric Rondeau
Fadi Fakhouri
Feriell Louillet
Jean-Philippe Coindre
Julien Hogan
P2860
P356
10.2215/CJN.06440616
P577
2016-10-31T00:00:00Z